Modern strategy for erythropoiesis-stimulating therapy in chronic kidney disease


O.N. Vetchinnikova

Anemic syndrome is closely linked with chronic kidney disease (CKD). Erythropoiesis-stimulating agents, preparations of erythropoietin, are a pathogenetic component of comprehensive therapy of renal anemia. The article discusses the current strategy of erythropoiesis-stimulating therapy in patients with CKD, based on an individual approach to establishing the target hemoglobin level and to the choice of the recombinant human erythropoietin preparation.

Similar Articles


Бионика Медиа